JLK Inspection, a company specializing in world-class AI-based medical imaging solutions and a company of the Born2Global Centre, was officially listed on the KOSDAQ index on December 11^th.

For two days, from December 2 to 3, JLK Inspection offered its shares for public subscription through Korea Investment and Securities Co., and the Korea Exchange approved the new listing of JLK Inspection on the KOSDAQ on December 10. The trading of the company's shares began on December 11 (expected subscription amount of KRW 18 billion and two million shares issued with a face value of KRW 100 per share and confirmed offer price of KRW 9,000). With this move, JLK Inspection has become the first Korean company in the AI-based medical industry to be listed on the index.

Founded in 2014, JLK Inspection is a company that specializes in the manufacture and supply of AI-based medical solutions.

It is particularly known for its development of AIHuB (AI Humanity Benefit), a medical platform that uses AI to diagnose and provide support for diagnosing diseases that affect all parts of the human body. AIHuB is a solution that analyzes a variety of medical images and clinical data using big data-based AI algorithms that are capable of not only detecting changes in the human body caused by diseases but also finding the root causes of those diseases. It has been designed to utilize conventional medical imaging equipment, such as x-ray and CT, as well as magnetic resonance imaging (MRI), magnetic resonance angiography (MRA), and ultrasound equipment, meaning that it can be used to detect a wide range of diseases.

JLK Inspection has been adopting different business models and accelerating its entry into the global market. Its technological expertise has been recognized around the world, with the company having secured a total of 14 certifications from Korea and abroad, including five medical device certifications from the Korean Ministry of Food and Drug Safety, seven CE marks for medical devices in Europe, and two certifications in Southeast Asia.

Regarding the company's listing on the KOSDAQ, JLK Inspection CEO Kim Dong-min said, "It is very significant that we are the first Korean company specialized in medical AI to be listed on the KOSDAQ." He added, "Now that we are listed on the KOSDAQ, we will accelerate our entry into the global market by establishing additional branches in major countries around the world and promoting joint research and clinical studies with overseas hospitals." Chief Executive Director Kim Jongkap of the Born2Global Centre also commented, "We will work even harder to support Korean companies in their efforts to enter the global market, thus paving the way for more companies to achieve success and be listed on stock exchanges like JLK Inspection."

JLK Inspection has been a member of the Born2Global Centre for three years, from 2017 to 2019, and has received a wide range of support for its advance into the global market.

Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,
for any copyright disputes involved in the reproduced articles,
please email: Julia.Zhang@ubmsinoexpo.com to motify or remove the content.